HCW Biologics IncNASDAQ:HCWBNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2946
- TODAY'S CHANGE (%)-0.0144 (-4.6602%)
- Bid / Lots0.2810/ 5
- Ask / Lots0.3000/ 80
- Open / Previous Close0.2830 / 0.3090
- Day Range
- 52 Week Range
- Volume25,936
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HCWB |
|---|---|---|
| 09:32 ET | 2729 | 0.282 |
| 09:46 ET | 100 | 0.29 |
| 10:02 ET | 300 | 0.3076 |
| 10:11 ET | 100 | 0.2901 |
| 10:31 ET | 16283 | 0.3 |
| 11:12 ET | 100 | 0.3075 |
| 11:14 ET | 100 | 0.3066 |
| 11:23 ET | 999 | 0.291 |
| 11:54 ET | 235 | 0.2911 |
| 02:03 ET | 2428 | 0.2947 |
| 02:43 ET | 199 | 0.2946 |
Nov 14, 2024
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights, from 4:40PM ET on Thursday Nov 14, 2024 by Dow Jones
4:40PM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights, from 4:40PM ET on Thursday Nov 14, 2024 by Dow Jones
4:40PM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HCW Biologics Inc | 11.1M | -0.3x | --- |
Senti Biosciences Inc | 9.8M | -0.1x | --- |
Ensysce Biosciences Inc | 10.0M | -0.2x | --- |
Dominari Holdings Inc | 10.7M | -0.4x | --- |
Intelligent Bio Solutions Inc | 6.5M | -0.1x | --- |
Addex Therapeutics Ltd | 12.2M | -0.7x | --- |
Company Information
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
Contact Information
- Headquarters
- 2929 N Commerce Pkwy, Miramar, Fl 33025MIRAMAR, FL, United States 33025
- Phone
- 954-842-2024
- Fax
- 954-842-2037
Executives
- Independent Chairman of the Board
- Scott Garrett
- Chief Executive Officer, Founder, Director
- Hing Wong
- Chief Financial Officer
- Rebecca Byam
- Senior Vice President of Business Development
- Lee Flowers
- Chief Scientific Officer, Vice President of Clinical Operations
- Peter Rhode
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.1M |
|---|---|
Revenue (TTM) | $3.9M |
Shares Outstanding | 37.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-1.04 |
Book Value | $0.37 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -947.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
